Unraveling the role of histone acetylation in sepsis biomarker discovery
Source check: Source checked. Not independent scientific confirmation.
Finding: Histone-acetylation transcriptomic analysis using LASSO, SVM-RFE and Boruta nominated three sepsis biomarkers; follow-up patient-blood/qPCR, MR and THP-1 knockdown assays support SFT2D1’s relation to inflammatory cytokines. This is a bounded biomarker/mechanistic result, not clinical benefit. This record is limited to the study result and does not establish independent replication or real-world benefit.
Technology: LASSO, SVM-RFE and Boruta
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Methods 2.1-2.5 and Results: GEO training/validation plus scRNA-seq; LASSO, SVM-RFE and Boruta prioritize BLOC1S1/NDUFA1/SFT2D1; THP-1 knockdown reduces CXCL10 and IL-6; patient blood/qPCR and MR are additional validation.
- Test and result
- Histone-acetylation transcriptomic analysis using LASSO, SVM-RFE and Boruta nominated three sepsis biomarkers; follow-up patient-blood/qPCR, MR and THP-1 knockdown assays support SFT2D1’s relation to inflammatory cytokines. This is a bounded biomarker/mechanistic result, not clinical benefit.
- Limitation / still unknown
- No prospective clinical benefit or broader external validity is established by the documented study.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1582181/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.